Article Versions Notes

Balasubramaniyam A, Ryan E, Brown D, Hamza T, Harrison W, Gan M, Sankhala RS, Chen W-H, Martinez EJ, Jensen JL, et al. Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines. 2023; 11(1):42. https://doi.org/10.3390/vaccines11010042

Balasubramaniyam, Arasu, Emma Ryan, Dallas Brown, Therwa Hamza, William Harrison, Michael Gan, Rajeshwer S. Sankhala, Wei-Hung Chen, Elizabeth J. Martinez, Jaime L. Jensen, and et al. 2023. "Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants" Vaccines 11, no. 1: 42. https://doi.org/10.3390/vaccines11010042

Balasubramaniyam, A., Ryan, E., Brown, D., Hamza, T., Harrison, W., Gan, M., Sankhala, R. S., Chen, W.-H., Martinez, E. J., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Mayer, S., King, J., Michael, N. L., Regules, J., Krebs, S., Rao, M., Matyas, G. R., ... Dutta, S. (2023). Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. Vaccines, 11(1), 42. https://doi.org/10.3390/vaccines11010042